Document is current
Any future updates will be listed below
-
Authors
Pelleg, Amir
Sirtori, Elena
Rolland, Jean-Francois
Mahadevan, Anu
-
Funding
Funding for this research was provided by:
Pennsylvania Department of Health (Biotechnology Research, Biotechnology Research, Biotechnology Research)
- License Information
-
More Information
Article History
Received: 15 December 2022
Accepted: 6 March 2023
First Online: 22 March 2023
Declarations
:
: Drs. Pelleg and Mahadevan are the CEOs of Danmir Therapeutics, LLC and Organix, Inc. respectively, which together are developing DT-0111 as a drug candidate for the treatment of several pulmonary disorders. Drs. Sirtori and Rolland declare no conflict of interest.
: N/A.
